"People with sclerosteosis lack a protein that acts as a brake on bone growth. Without that protein, bones grow abnormally thick. It stood to reason, researchers thought, that a drug that could block the protein in patients with osteoporosis would encourage bone regrowth. Amgen's scientists created hundreds of antibodies that they tested to determine which might be able to get in the way of the protein. It took them three and a half years of research before they were able to identify the best antibody to inhibit the protein. Then NASA came calling." It's an unfortunate situation for those with the rare conditions; there's a lot more potential profit in finding a way to genetically prevent pain for billions of people than it is to cure the handful with the condition.
They have a crowdfunding appeal on experiment.com looking for help in sequencing the black rhino genome. At this writing, it has two days to run and has only raised $12,831 of its $16,500 goal. The results will be open sourced, and once the black rhino is on its way to salvation, they plan to work on the white rhino, then move on to killing the black market for ivory and tiger pelts, which don't sell for as much as rhino horns but are valuable enough to keep an international horde of poachers in business.
The company already mulls expanding its production principle to other, lucrative wild animal trades such as the claws of tigers and lions. Pembient is however a young company — for all their ingenuity, will their ambitions to take on such a colossal black market be realized?